NEW YORK, Oct 3- Salix Pharmaceuticals Ltd, citing a "changed political environment," said on Friday it had scrapped a deal with Italy's Cosmo Pharmaceuticals SpA that would have allowed it to shift its tax base from the United States to Europe. In recent months, Salix has also been pursued by Allergan Inc as the Botox maker seeks to fend off a $53 billion hostile...
Raleigh, North Carolina- based Salix, which makes drugs for gastrointestinal disorders, said in July it would merge with Cosmo's Irish subsidiary, a deal that would allow Salix to move its tax domicile abroad in a practice known as inversion. The development path of the pipeline continued in the meantime, so this termination has no effect on value creation, "said...
Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions.
BOSTON/ NEW YORK, Oct 1- Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.
CNBC's David Faber reports on the strong statement from investor shareholder advisory firm ISS to Allergan about the importance of the shareholders' opinions on any buyout strategy.
Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. It will compete with Nektar Therapeutics and AstraZeneca Plc's oral drug Movantik, approved by the FDA earlier this month for the same patient population.
Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. Salix, which is merging with Cosmo Pharmaceuticals SpA's Irish subsidiary, is in talks with Allergan Inc and Actavis Plc about a potential sale, sources have told Reuters in recent weeks.
Another large shareholder of Botox-maker Allergan is expressing concern over the company's corporate governance amid its fight to hold off hostile acquirer Valeant.
Sept 26- T. Rowe Price, the second largest shareholder in Allergan Inc, said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board's corporate governance.
Sept 25- Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.
Allergan Inc has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals Inc.. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.
Sept 24- Allergan Inc is in buyout talks with Actavis Plc in addition to Salix Pharmaceuticals Ltd, CNBC reported on Wednesday, as the company tries to fend off a takeover attempt by Valeant Pharmaceuticals Inc. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.
CNBC's David Faber reports Actavis and Salix are engaged in early stage discussions about a deal. Faber says Allegan's pursuit of Slaix continues, but has slowed.
Given negatives in the market, it only makes sense to revisit investments. Should you stay the course?
Some of Tuesday's midday movers:
NEW YORK, Sept 23- U.S. stocks were set for a lower open on Tuesday, putting the S&P on pace for a third straight fall, as conflict in the Middle East intensified and after the U.S.
CNBC's David Faber reports significant talks are taking place between Allergan and Salix Pharmaceuticals, and how the potential deal impacts Valeant. Jim Cramer explains how Wall Street perceives the potential buy.
NEW YORK, Sept 23- U.S.-listed shares of Tekmira Pharmaceuticals were climbing on Tuesday, up 8.9 percent at $25.70 as one of the most actively trades Nasdaq stocks as its Ebola drug will be one of several to be tested in West Africa in a bid to win fast-track trials.
Some of the names on the move ahead of the open.
Since Valeant and Pershing Square offered to buy Allergan on April 22, Allergan has consistently rejected their offer, saying it undervalues the company. "We believe Valeant and Pershing Square are conducting a fishing expedition for their own purposes and contrary to the best interests of Allergan stockholders," Allergan's spokesman said on Monday.